Oregon Public Employees Retirement Fund increased its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Rating) by 2.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,220 shares of the company’s stock after purchasing an additional 300 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in Pacira BioSciences were worth $810,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. First Horizon Advisors Inc. grew its stake in Pacira BioSciences by 14,433.3% during the 2nd quarter. First Horizon Advisors Inc. now owns 436 shares of the company’s stock worth $25,000 after purchasing an additional 433 shares in the last quarter. Neo Ivy Capital Management acquired a new position in Pacira BioSciences during the 2nd quarter worth $44,000. Heritage Wealth Management LLC acquired a new position in Pacira BioSciences during the 2nd quarter worth $152,000. Quantbot Technologies LP acquired a new position in Pacira BioSciences during the 2nd quarter worth $156,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its stake in Pacira BioSciences by 7.4% during the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,930 shares of the company’s stock worth $156,000 after purchasing an additional 203 shares in the last quarter.
Pacira BioSciences Stock Up 2.8 %
Shares of NASDAQ PCRX opened at $38.35 on Wednesday. The stock has a market cap of $1.76 billion, a PE ratio of 93.54 and a beta of 0.76. The company has a quick ratio of 3.32, a current ratio of 4.06 and a debt-to-equity ratio of 0.93. Pacira BioSciences, Inc. has a 52-week low of $35.35 and a 52-week high of $82.16. The business has a 50-day moving average price of $42.04 and a 200 day moving average price of $50.10.
Analyst Upgrades and Downgrades
Several research analysts recently commented on PCRX shares. Cowen lowered their target price on Pacira BioSciences from $54.00 to $50.00 in a research note on Wednesday, December 14th. Jefferies Financial Group assumed coverage on Pacira BioSciences in a research report on Friday, October 21st. They set a “buy” rating and a $66.00 price objective for the company. HC Wainwright lowered their price objective on Pacira BioSciences from $83.00 to $76.00 and set a “buy” rating for the company in a research report on Friday, November 4th. Wedbush reaffirmed a “buy” rating and set a $88.00 price objective on shares of Pacira BioSciences in a research report on Wednesday, December 21st. Finally, StockNews.com assumed coverage on Pacira BioSciences in a research report on Wednesday, October 12th. They set a “hold” rating for the company. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Pacira BioSciences currently has a consensus rating of “Moderate Buy” and an average price target of $65.50.
Pacira BioSciences Profile
Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves.
- Get a free copy of the StockNews.com research report on Pacira BioSciences (PCRX)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- Is It Time To Get Aggressive With Defense Stocks?
Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.